SASoha Shawqi Albayat

Soha Shawqi Albayat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soha Shawqi Albayat has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sovereignty, equity, solidarity: progress on the Global Health Emergency Corps

    by Scott F Dowell, Christophe Schmachtel, Abdi Mahamud, Abdou Salam Gueye, Andrew Lee, Armand Bejtullahu, Carita Davis, Ciro Ugarte, Didier K Ekouevi, Eduardo S Gudo, et al.

    Five years after the start of the COVID-19 pandemic, pushback against global health initiatives is common amidst declining health spending and growing nationalism. 1 2 But the threat of future pandemics, such as that posed by the widening mammalian transmission of influenza A (H5N1), underscores the need for strengthened collaboration. The new Global Health Emergency Corps (GHEC) is a body of experts in ministries and agencies in every country who work on health emergencies and the global ecosystem through which they coordinate. The GHEC framework3 aims to support the development of consistent workforce capacity across the core health emergency components,4 complemented by surge teams that can be deployed as needed through pre-agreed governmental mechanisms, and emergency leaders who are embedded within the highest level of health security coordination in the government.


  • Open Access

    Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar

    by Khadieja Osman, Jesha Mundodan, Juel Chowdhury, Rejoice Ravi, Rekayahouda Baaboura, Jeevan Albuquerque, Bilal Riaz, Reem Yusuf Emran, Khatija Batoul, Abdul Mahmood Esameldin, et al.

    Qatar was also hit hard by the global pandemic of SARS-CoV-2, with the original virus, Alpha variant, Beta variant, Omicron BA.1 and BA.2 variants, Omicron BA.4 and BA.5 variants, and Delta variant, sequentially. The two-dose primary series of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against SARS-CoV-2 infection has been approved for use in 30 µg formulations among children and adolescents aged 12–17 years as of 16 May 2021. This study aimed at estimating the effectiveness of the 30 µg BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine against the pre-Omicron variants of SARS-CoV-2 infection in children and adolescents aged 12–17 years residing in Qatar. A test-negative matched case-control study was conducted. The subjects included any child or adolescent aged 12–17 years who had been tested for SARS-CoV-2 using RT-PCR tests performed on nasopharyngeal or oropharyngeal swabs, as part of contact tracing, between June and November 2021, and was eligible to receive the BNT162b2 vaccine as per the national guidelines. Data regarding 14,161 children/adolescents meeting inclusion–exclusion criteria were retrieved from the national Surveillance and Vaccine Electronic System (SAVES). Of the total, 3.1% (444) were positive for SARS-CoV-2. More than half (55.96%) were vaccinated with two doses of Pfizer-BioNTech-mRNA COVID-19 vaccine. Amongst those immunized with two doses, 1.2% tested positive for SARS-CoV-2, while 5.6% amongst the unvaccinated tested positive. The vaccine effectiveness was calculated to be 79%. Pfizer-BioNTech mRNA COVID-19 vaccine provides protection from COVID-19 infection for children/adolescents; hence, it is crucial to ensure they receive the recommended vaccines.


  • Open Access

    Clinical manifestations and outcome of Mpox infection in Qatar: An observational study during the 2022 outbreak

    by Ahmed Zaqout, Joanne Daghfal, Waqar Munir, Alaaeldin Abdelmajid, Soha S. Albayat, Mohammed Abukhattab, Muna A. Al-Maslamani


  • Open Access

    Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar

    by Khadieja Osman Hassan Elhag, Jesha Mohammedali Mundodan, Juel Bikhash Chowdhry, Rejoice Puthuchira Ravi, Rekaya Houda Baaboura, Jeevan Albuquerque, Bilal Riaz, Reem Yusuf Emran, Khatija Batoul, Abdul Mahmood Esameldin, et al.

    Qatar experienced five SARS-CoV-2 waves dominated sequentially by the original virus, Alpha, Beta, Omicron BA.1 and BA.2, and Omicron BA.4 and BA.5, in addition to a prolonged low-incidence phase dominated by the Delta variant. The two-dose primary series of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against SARS-CoV-2 infection has been approved for use in 10µg formulations among children and adolescents aged 12-17 years as of May 16, 2021. This study aimed at estimating the effectiveness of the 30µg BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine against the pre-Omicron variants of SARS-CoV-2 infection in children and adolescents aged 12-17 years residing in Qatar. A test-negative matched case-control study was conducted where any child or adolescent aged 12-17 years who had been tested for SARS-CoV-2, RT-PCR tests performed on nasopharyngeal or oropharyngeal swabs, as part of contact tracing, between June and November 2021 and eligible to receive the BNT162b2 vaccine as per the national guidelines. Data regarding 14,161 children/adolescents meeting inclusion-exclusion criteria were retrieved from the national Surveillance and Vaccine Electronic System (SAVES). Of the total, 3.1% (444) were positive for SARSCoV-2. More than half (55.96%) were vaccinated with two doses of Pfizer-BioNTech-mRNA COVID-19 vaccine. Amongst those immunized with two doses, 1.2% tested positive for SARS CoV2, while 5.6% amongst the unvaccinated tested positive. The vaccine effectiveness was calculated to be 79%. Pfizer-BioNTech mRNA COVID-19 vaccine provides protection from COVID-19 infection for children/adolescents, hence it is crucial to ensure they receive the recommended vaccines.

  • Open Access

    Key Lessons from COVID-19: A Narrative Review Describing Qatar’s Multifactorial Approach in Executing a Vaccination Campaign

    by Soha Albayat, Muna Almaslamani, Hamad Alromaihi, Hayat Khogali, Jesha Mundodan, Jean Joury, Hammam Haridy

    Widespread vaccination programs have been implemented in many countries to curtail the COVID-19 pandemic, with varying success and challenges. To better understand the successes and challenges of the global COVID-19 response in the face of emerging new variants and epidemiologic data, we discuss how Qatar engaged the healthcare sector, governmental bodies, and the populace to combat COVID-19, with a focus on the country’s vaccination strategy. This narrative provides the history and timeline of the Qatar COVID-19 vaccination campaign; factors that helped the vaccination campaign and the transferable lessons learned are discussed. Details regarding how Qatar responded to challenges, such as vaccine hesitancy and mitigation of misinformation, are highlighted. Qatar was one of the first countries to procure the BNT162b2 (Comirnaty®; Pfizer-BioNTech, Pfizer Inc., New York, NY, USA) and mRNA-1273 (Spikevax®; Moderna, Cambridge, MA, USA) COVID-19 vaccines. A relatively high vaccination rate and low case mortality rate (0.14% as of 4 January 2023) was observed in Qatar compared with other countries (global case mortality rate, 1.02%). Learnings will be carried forward as a basis for addressing this evolving pandemic and any future national emergencies in Qatar.


  • Open Access

    Association between Multimorbidity and COVID-19 Mortality in Qatar: A Cross-Sectional Study

    by Khalid AbouGalala, Basant Elsayed, Mohamed Elmarasi, Mona Kotob, Reham Taha, Fardous Abbasher, Ahmed Amarah, Mariam El Hamawi, Soha S. Albayat, Jazeel Abdulmajeed, et al.

    This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.


  • Open Access

    Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

    by Devendra Bansal, Jazeel Abdulmajeed, Maha H. M. A. Al-Shamali, Soha S. A. Albayat, Sayed M. Himatt, Farhan S. Cyprian, Tawanda Chivese, Jesha M. A. Mundodan, Hayat S. Khogali, Rekayahouda Baaboura, et al.

    Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed to design-related bias by conducting a study only among those detected with a first SARS-CoV-2 infection. We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 January 2021 and 20 February 2022. Cases were those detected with first SARS-CoV-2 infection requiring intensive care (hard outcome), while controls were those detected with first SARS-CoV-2 infection who recovered without the need for intensive care. Cases and controls were matched in a 1:30 ratio for the calendar month of infection and the comorbidity category. Duration and magnitude of conditional vaccine effectiveness against requiring intensive care and the number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care was estimated for the mRNA (BNT162b2/mRNA-1273) vaccines. Conditional vaccine effectiveness against requiring intensive care was 59% (95% confidence interval (CI), 50 to 76) between the first and second dose, and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 6, 6 to 9, and 9 to 12 months after the second dose. This study demonstrates that, contrary to mainstream reports using hierarchical measures of effectiveness, conditional vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA-based vaccines.


  • Open Access

    Validation of Rapid Antibody (IgG-IgM) Test Kit for SARS-CoV-2 Infection in Qatar

    by Jesha Mundodan, Samina Hasnain, Hayat Khogali, Soha Shawqi Al Bayat, Dina Ali, Saif Alateeg, Hamad Eid Al-Romaihi, Mohammed Hamad J. Al Thani

    Background: In response to the growing coronavirus disease 2019 (COVID-19) pandemic and the shortage of laboratory based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed rapid and easy to use devices to facilitate testing outside laboratory settings. These kits are either based on detection of proteins from SARS-CoV-2 virus or detection of antigen or human antibodies generated in response to the infection. However, it is important to understand their performance characteristics and they must be validated in the local population setting. Design and methods: The objective is to assess the validity of the rapid test for IgG and IgM immunoglobulins compared to the current gold standard reverse transcription polymerase chain reaction (RT-PCR) test. A total of 16951 asymptomatic individuals were tested by the Ministry of Public Health track-and-trace team using both rapid immunodiagnostic test and RT-PCR as part of screening across various random settings with potential risk of community interaction prior to gradual lifting of restrictions in Qatar. Rapid test was considered to be posiive if both IgG and IgM are positive, while only IgG/IgM positive was considered as rapid test negative. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Results: The sensitivity of rapid test kit was found to be 0.9%, whereas the specificity was found to be 97.8%. the PPV was found to be 0.3% whereas the NPV was found to be 99.4%. Conclusions: Based on the outcome and results of the study, it appears that the sensitivity and PPV of the rapid antibody test are low. As such, this test is not recommended for use to assist in taking clinic-based decisions or decisions related to quarantine/isolation.


  • Open Access

    Flyers Tooth Squeeze - Current Concepts and Future Needs - A Review

    by Sohaib Arshad, Soha Shawqi Albayat, Sameer Badri Al-Mhanna, Raja Azman Awang, Hina Abbas, Fatima Tehreem

    BACKGROUND The flyers tooth or the tooth squeeze is the toothache during air travel, termed as Barodontalgia / Aerodontalgia by researchers. It was first identified as an in-flight physiologic and pathologic phenomenon at the start of the 20th century. With the introduction of the scuba in the 1940s, many in-flight manifestations caused by barometric variations were discovered to be synonymous with diving as well. Scuba diving is a type of underwater diving where the diver breathes underwater using equipment independent of the surface supply. It can be performed for fun or a living in various settings, including the scientific, army, and public security responsibilities. However, most commercial diving employs surface-supplied diving equipment wherever possible. Battle divers and assault swimmers are all terms for scuba divers who participate in clandestine military operations. Most cases of barodontalgia occur during ascent. The origin of the discomfort is also affected by the underlying pathology. In general, pain on the rise is associated with essential pulp disease, i.e., pulpitis and pain on descent with pulp necrosis. The pain subsides typically as the patient returns to the onset stage or the ground ambient level, although it can last longer if exacerbated by periapical infection. The Fédération dentaire internationale FDI advises that pilots, divers, and other professionals undergo yearly exams, as well as appropriate dental hygiene education from dentists, after a dental procedure that necessitates an anaesthetic or seven days after a dental procedure until travelling, teeth with pre-existing substantial restorations should have a cold-test examination or periapical radiographs taken to rule out occult pulp necrosis. It is appropriate to arrange outpatient dental appointments for a suitable period until the next scheduled flight. The possible treatment modalities vary from immediate relief to the control of infection and further subsequent treatment procedures. In recent years, the airline industry and scuba diving have grown in popularity, but little is known about the oral issues linked with high altitude. It is entirely the obligation of dental health experts to give the finest dental care to aviators as well as raise knowledge of the risks of dental treatments at higher altitudes. Dentists and flight crew members should both have appropriate awareness of barodontalgia and its role in its prevention. Particular attention should be given by the otolaryngologist and must be aware of the issues and hazards associated with scuba diving. KEY WORDS Aerodontalgia, Barodontalgia, Flyer's Tooth, Pulpitis; Scuba, Tooth Squeeze